Evidence map›Paper›PMID 32473302›Full record

SynthesisAnnals of oncology : official journal of the European Society for Medical Oncology2020

Prognostic gene expression signature for high-grade serous ovarian cancer.

J Millstein, T Budden, E L Goode, M S Anglesio, A Talhouk, M P Intermaggio, H S Leong, S Chen, W Elatre, B Gilks and 115 more

Abstract readMeta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Annals of oncology : official journal of the European Society for Medical Oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 90 papers.

0numbers the graph read from it
0cells of the map it votes in
90citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

90 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. BeyondmedRxiv : the preprint server for health sciences · 2025
    Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

30 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

125 authors.

J MillsteinDivision of Biostatistics, Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, USA.
T BuddenSchool of Women's and Children's Health, Faculty of Medicine, University of NSW Sydney, Sydney, Australia; CRUK Manchester Institute, The University of Manchester, Manchester, UK.
E L GoodeDepartment of Health Science Research, Division of Epidemiology, Mayo Clinic, Rochester, USA.
M S AnglesioBritish Columbia's Ovarian Cancer Research (OVCARE) Program, BC Cancer, Vancouver General Hospital, and University of British Columbia, Vancouver, Canada; Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, Canada; Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, Canada.
A TalhoukBritish Columbia's Ovarian Cancer Research (OVCARE) Program, BC Cancer, Vancouver General Hospital, and University of British Columbia, Vancouver, Canada; Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, Canada.
M P IntermaggioSchool of Women's and Children's Health, Faculty of Medicine, University of NSW Sydney, Sydney, Australia.
H S LeongPeter MacCallum Cancer Center, Melbourne, Australia.
S ChenCenter for Cancer Prevention and Translational Genomics, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, USA.
W ElatreDepartment of Pathology, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, USA.
B GilksBritish Columbia's Ovarian Cancer Research (OVCARE) Program, BC Cancer, Vancouver General Hospital, and University of British Columbia, Vancouver, Canada; Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, Canada.
T NazeranBritish Columbia's Ovarian Cancer Research (OVCARE) Program, BC Cancer, Vancouver General Hospital, and University of British Columbia, Vancouver, Canada.
M VolchekAnatomical Pathology, Royal Women's Hospital, Parkville, Australia.
R C BentleyDepartment of Pathology, Duke University Hospital, Durham, USA.
C WangDepartment of Health Science Research, Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, USA.
D S ChiuBritish Columbia's Ovarian Cancer Research (OVCARE) Program, BC Cancer, Vancouver General Hospital, and University of British Columbia, Vancouver, Canada.
S KommossDepartment of Women's Health, Tuebingen University Hospital, Tuebingen, Germany.
S C Y LeungBritish Columbia's Ovarian Cancer Research (OVCARE) Program, BC Cancer, Vancouver General Hospital, and University of British Columbia, Vancouver, Canada.
J SenzBritish Columbia's Ovarian Cancer Research (OVCARE) Program, BC Cancer, Vancouver General Hospital, and University of British Columbia, Vancouver, Canada; Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, Canada.
A LumBritish Columbia's Ovarian Cancer Research (OVCARE) Program, BC Cancer, Vancouver General Hospital, and University of British Columbia, Vancouver, Canada.
V ChowBritish Columbia's Ovarian Cancer Research (OVCARE) Program, BC Cancer, Vancouver General Hospital, and University of British Columbia, Vancouver, Canada.
H SudderuddinBritish Columbia's Ovarian Cancer Research (OVCARE) Program, BC Cancer, Vancouver General Hospital, and University of British Columbia, Vancouver, Canada.
R MackenzieBritish Columbia's Ovarian Cancer Research (OVCARE) Program, BC Cancer, Vancouver General Hospital, and University of British Columbia, Vancouver, Canada.
J GeorgeThe Jackson Laboratory for Genomic Medicine, Farmington, USA.
AOCS GroupPeter MacCallum Cancer Center, Melbourne, Australia; Department of Genetics and Computational Biology, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia; Centre for Cancer Research, The Westmead Institute for Medical Research, The University of Sydney, Sydney, Australia.
S FeredayPeter MacCallum Cancer Center, Melbourne, Australia; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Australia.
J HendleyPeter MacCallum Cancer Center, Melbourne, Australia; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Australia.
N TraficantePeter MacCallum Cancer Center, Melbourne, Australia; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Australia.
H SteedDepartment of Obstetrics and Gynecology, Division of Gynecologic Oncology, Royal Alexandra Hospital, Edmonton, Canada.
J M KoziakAlberta Health Services-Cancer Care, Calgary, Canada.
M KöbelDepartment of Pathology and Laboratory Medicine, University of Calgary, Foothills Medical Center, Calgary, Canada.
I A McNeishDivision of Cancer and Ovarian Cancer Action Research Centre, Department Surgery & Cancer, Imperial College London, London, UK; Institute of Cancer Sciences, University of Glasgow, Glasgow, UK.
T GoranovaCancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK.
D EnnisDivision of Cancer and Ovarian Cancer Action Research Centre, Department Surgery & Cancer, Imperial College London, London, UK; Institute of Cancer Sciences, University of Glasgow, Glasgow, UK.
G MacintyreCancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK.
D Silva De SilvaCancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK.
T Ramón Y CajalMedical Oncology Service, Hospital Sant Pau, Barcelona, Spain.
J García-DonasHM Hospitales D Centro Integral Oncológico HM Clara Campal, Madrid, Spain.
S Hernando PoloMedical Oncology Service, Hospital Universitario Funcacion Alcorcon, Alcorcón, Spain.
G C RodriguezDivision of Gynecologic Oncology, NorthShore University HealthSystem, University of Chicago, Evanston, USA.
K L Cushing-HaugenProgram in Epidemiology, Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, USA.
H R HarrisProgram in Epidemiology, Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, USA; Department of Epidemiology, University of Washington, Seattle, USA.
C S GreeneDepartment of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA.
R A ZelayaDepartment of Genetics, Geisel School of Medicine at Dartmouth, Hanover, USA.
S BehrensDivision of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
R T FortnerDivision of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
P SinnDepartment of Pathology, Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.
E HerpelDepartment of Pathology, Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany; National Center for Tumor Diseases, University Hospital and German Cancer Research Center, Heidelberg, Germany.
J LesterDavid Geffen School of Medicine, Department of Obstetrics and Gynecology, University of California at Los Angeles, Los Angeles, USA; Women's Cancer Program at the Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, USA.
J LubińskiDepartment of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland.
O OszurekDepartment of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland.
A TołoczkoDepartment of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland.
C CybulskiDepartment of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland.
J MenkiszakDepartment of Gynecological Surgery and Gynecological Oncology of Adults and Adolescents, Pomeranian Medical University, Szczecin, Poland.
C L PearceDepartment of Epidemiology, University of Michigan School of Public Health, Ann Arbor, USA; Department of Preventive Medicine, Keck School of Medicine, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, USA.
M C PikeDepartment of Preventive Medicine, Keck School of Medicine, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, USA; Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, USA.
C TsengDepartment of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, USA.
J AlsopCentre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, UK.
V RheniusCentre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, UK.
H SongCentre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, UK.
M Jimenez-LinanDepartment of Pathology, Addenbrooke's Hospital NHS Trust, Cambridge, UK.
A M PiskorzCancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK.
A Gentry-MaharajMRC Clinical Trials Unit at UCL, Institute of Clinical Trials & Methodology, University College London, London, UK.
C KarpinskyjMRC Clinical Trials Unit at UCL, Institute of Clinical Trials & Methodology, University College London, London, UK.
M WidschwendterDepartment of Women's Cancer, Institute for Women's Health, University College London, London, UK.
N SinghDepartment of Pathology, Barts Health National Health Service Trust, London, UK.
C J KennedyCentre for Cancer Research, The Westmead Institute for Medical Research, The University of Sydney, Sydney, Australia; Department of Gynaecological Oncology, Westmead Hospital, Sydney, Australia.
R SharmaPathology West ICPMR Westmead, Westmead Hospital, The University of Sydney, Sydney, Australia; University of Western Sydney at Westmead Hospital, Sydney, Australia.
P R HarnettCentre for Cancer Research, The Westmead Institute for Medical Research, The University of Sydney, Sydney, Australia; The Crown Princess Mary Cancer Centre Westmead, Sydney-West Cancer Network, Westmead Hospital, Sydney, Australia.
B GaoCentre for Cancer Research, The Westmead Institute for Medical Research, The University of Sydney, Sydney, Australia; The Crown Princess Mary Cancer Centre Westmead, Sydney-West Cancer Network, Westmead Hospital, Sydney, Australia.
S E JohnattyDepartment of Genetics and Computational Biology, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia.
R SayerDepartment of Gynaecological Oncology, Westmead Hospital, Sydney, Australia.
J BorosCentre for Cancer Research, The Westmead Institute for Medical Research, The University of Sydney, Sydney, Australia; Department of Gynaecological Oncology, Westmead Hospital, Sydney, Australia.
S J WinhamDepartment of Health Science Research, Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, USA.
G L KeeneyDepartment of Laboratory Medicine and Pathology, Division of Anatomic Pathology, Mayo Clinic, Rochester, USA.
S H KaufmannDepartment of Oncology, Mayo Clinic, Rochester, USA; Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, USA.
M C LarsonDepartment of Health Science Research, Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, USA.
H LukCancer Epidemiology Program, University of Hawaii Cancer Center, Honolulu, USA.
B Y HernandezCancer Epidemiology Program, University of Hawaii Cancer Center, Honolulu, USA.
P J ThompsonSamuel Oschin Comprehensive Cancer Institute, Cancer Prevention and Genetics Program, Cedars-Sinai Medical Center, Los Angeles, USA.
L R WilkensCancer Epidemiology Program, University of Hawaii Cancer Center, Honolulu, USA.
M E CarneyJohn A. Burns School of Medicine, Department of Obstetrics and Gynecology, University of Hawaii, Honolulu, USA.
B TrabertDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, USA.
J LissowskaDepartment of Cancer Epidemiology and Prevention, M Sklodowska Curie National Research Institute of Oncology, Warsaw, Poland.
L BrintonDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, USA.
M E ShermanDepartment of Health Sciences Research, Mayo Clinic College of Medicine, Jacksonville, USA.
C BodelonDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, USA.
S HinsleyCancer Research UK Clinical Trials Unit, Institute of Cancer Sciences, University of Glasgow, Glasgow, UK.
L A LewsleyCancer Research UK Clinical Trials Unit, Institute of Cancer Sciences, University of Glasgow, Glasgow, UK.
R GlasspoolDepartment of Medical Oncology, Beatson West of Scotland Cancer Centre and University of Glasgow, Glasgow, UK.
S N BanerjeeThe Royal Marsden NHS Foundation Trust and Institute of Cancer Research, London, UK.
E A StronachDivision of Cancer and Ovarian Cancer Action Research Centre, Department Surgery & Cancer, Imperial College London, London, UK.
P HaluskaDepartment of Oncology, Mayo Clinic, Rochester, USA.
I Ray-CoquardCentre Leon Berard and University Claude Bernard Lyon 1, Lyon, France.
S MahnerDepartment of Obstetrics and Gynecology, University Hospital, LMU Munich, Munich, Germany.
B WinterhoffDepartment of Obstetrics, Gynecology and Women's Health, University of Minnesota, Minneapolis, USA.
D SlamonDavid Geffen School of Medicine, Department of Medicine Division of Hematology and Oncology, University of California at Los Angeles, Los Angeles, USA.
D A LevineGynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, USA; Gynecologic Oncology, Laura and Isaac Pearlmutter Cancer Center, NYU Langone Medical Center, New York, USA.
L E KelemenHollings Cancer Center and Department of Public Health Sciences, Medical University of South Carolina, Charleston, USA.
J BenitezCentro de Investigación en Red de Enfermedades Raras (CIBERER), Madrid, Spain; Human Cancer Genetics Programme, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.
J Chang-ClaudeDivision of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany; Cancer Epidemiology Group, University Cancer Center Hamburg (UCCH), University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
J GronwaldDepartment of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland.
A H WuDepartment of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, USA.
U MenonMRC Clinical Trials Unit at UCL, Institute of Clinical Trials & Methodology, University College London, London, UK.
M T GoodmanSamuel Oschin Comprehensive Cancer Institute, Cancer Prevention and Genetics Program, Cedars-Sinai Medical Center, Los Angeles, USA.
J M SchildkrautDepartment of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, USA.
N WentzensenDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, USA.
R BrownDivision of Cancer and Ovarian Cancer Action Research Centre, Department of Surgery and Cancer, Imperial College London, London, UK.
A BerchuckDepartment of Gynecologic Oncology, Duke University Hospital, Durham, USA.
G Chenevix-TrenchDepartment of Genetics and Computational Biology, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia.
A deFazioCentre for Cancer Research, The Westmead Institute for Medical Research, The University of Sydney, Sydney, Australia; Department of Gynaecological Oncology, Westmead Hospital, Sydney, Australia.
S A GaytherCenter for Bioinformatics and Functional Genomics and the Cedars Sinai Genomics Core, Cedars-Sinai Medical Center, Los Angeles, USA.
M J GarcíaHuman Cancer Genetics Programme, Spanish National Cancer Research Centre (CNIO), Madrid, Spain; Biomedical Network on Rare Diseases (CIBERER), Madrid, Spain.
M J HendersonChildren's Cancer Institute, Lowy Cancer Research Centre, University of NSW Sydney, Sydney, Australia.
M A RossingProgram in Epidemiology, Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, USA; Department of Epidemiology, University of Washington, Seattle, USA.
A Beeghly-FadielDivision of Epidemiology, Department of Medicine, Vanderbilt Epidemiology Center, Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, USA.
P A FaschingDavid Geffen School of Medicine, Department of Medicine Division of Hematology and Oncology, University of California at Los Angeles, Los Angeles, USA; Department of Gynecology and Obstetrics, Comprehensive Cancer Center ER-EMN, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nuremberg, Erlangen, Germany.
S OrsulicDavid Geffen School of Medicine, Department of Obstetrics and Gynecology, University of California at Los Angeles, Los Angeles, USA; Women's Cancer Program at the Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, USA.
B Y KarlanDavid Geffen School of Medicine, Department of Obstetrics and Gynecology, University of California at Los Angeles, Los Angeles, USA; Women's Cancer Program at the Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, USA.
G E KonecnyDavid Geffen School of Medicine, Department of Medicine Division of Hematology and Oncology, University of California at Los Angeles, Los Angeles, USA.
D G HuntsmanBritish Columbia's Ovarian Cancer Research (OVCARE) Program, BC Cancer, Vancouver General Hospital, and University of British Columbia, Vancouver, Canada; Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, Canada; Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, Canada; Department of Molecular Oncology, BC Cancer Research Centre, Vancouver, Canada.
D D BowtellPeter MacCallum Cancer Center, Melbourne, Australia; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Australia.
J D BrentonCancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK.
J A DohertyHuntsman Cancer Institute, Department of Population Health Sciences, University of Utah, Salt Lake City, USA.
P D P PharoahCentre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, UK; Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.
S J RamusSchool of Women's and Children's Health, Faculty of Medicine, University of NSW Sydney, Sydney, Australia; Adult Cancer Program, Lowy Cancer Research Centre, University of NSW Sydney, Sydney, Australia. Electronic address: s.ramus@unsw.edu.au.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
USC/NORRIS COMPREHENSIVE CANCER CENTER (CORE) SUPPORTP30CA014089 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI MYLES G COCKBURN · 1985 to 2026
$181.4M
UCLA Clinical Translational Science InstituteUL1TR001881 · NCATS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ARLEEN F. BROWN, ARASH NAEIM · 2016 to 2026
$118.1M
Hormone-Related CancersZIACP010126 · NCI · DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS · PI GIERACH, GRETCHEN · 2009 to 2025
$103.5M
UTAH REGIONAL CANCER CENTERP30CA042014 · NCI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI KATHARINE S ULLMAN · 1986 to 2026
$72.6M
Shared Resource ManagementP30CA034196 · NCI · JACKSON LABORATORY · PI William Carl Skarnes · 1985 to 2026
$61.9M
UCLA Clinical and Translational Science InstituteUL1TR000124 · NCATS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI DUBINETT, STEVEN M. · 2012 to 2015
$57.0M
Use of microfluidic tumor cultures to enable clinical trials of therapies for ovarian cancerP50CA136393 · NCI · MAYO CLINIC ROCHESTER · PI ELLEN L. GOODE · 2009 to 2026
$37.0M
Statistical Methods for Integrative Genomics in CancerP01CA196569 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI David V Conti · 2016 to 2026
$25.5M
Identifying Prognostic Markers and Therapeutic Targets for Serous Ovarian CancerR01CA172404 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI RAMUS, SUSAN J · 2013 to 2017
$2.9M
Characterizing Molecular Subtypes of Ovarian Cancer in African-American WomenR01CA200854 · NCI · UNIVERSITY OF UTAH · PI DOHERTY, JENNIFER A., SCHILDKRAUT, JOELLEN M. · 2016 to 2021
$2.8M
Epidemiologic factors and survival by molecular subtypes of ovarian cancerR01CA168758 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI DOHERTY, JENNIFER A., ROSSING, MARY ANNE · 2013 to 2016
$2.6M
Cancer Research UK 13086Cancer Research UK 15601Cancer Research UK 22905Cancer Research UK A16561Medical Research Council MC_UU_12023/20NCATS NIH HHS UL1 TR000124NCATS NIH HHS UL1 TR001881NCI NIH HHS K22 CA193860NCI NIH HHS P01 CA196569NCI NIH HHS P30 CA008748NCI NIH HHS P30 CA014089NCI NIH HHS P30 CA034196NCI NIH HHS P50 CA136393NCI NIH HHS R01 CA168758NCI NIH HHS R01 CA172404NCI NIH HHS R01 CA200854
6 · The paper itself

Abstract

backgroundMedian overall survival (OS) for women with high-grade serous ovarian cancer (HGSOC) is ∼4 years, yet survival varies widely between patients. There are no well-established, gene expression signatures associated with prognosis. The aim of this study was to develop a robust prognostic signature for OS in patients with HGSOC. PATIENTS AND

methodsExpression of 513 genes, selected from a meta-analysis of 1455 tumours and other candidates, was measured using NanoString technology from formalin-fixed paraffin-embedded tumour tissue collected from 3769 women with HGSOC from multiple studies. Elastic net regularization for survival analysis was applied to develop a prognostic model for 5-year OS, trained on 2702 tumours from 15 studies and evaluated on an independent set of 1067 tumours from six studies.

resultsExpression levels of 276 genes were associated with OS (false discovery rate < 0.05) in covariate-adjusted single-gene analyses. The top five genes were TAP1, ZFHX4, CXCL9, FBN1 and PTGER3 (P < 0.001). The best performing prognostic signature included 101 genes enriched in pathways with treatment implications. Each gain of one standard deviation in the gene expression score conferred a greater than twofold increase in risk of death [hazard ratio (HR) 2.35, 95% confidence interval (CI) 2.02-2.71; P < 0.001]. Median survival [HR (95% CI)] by gene expression score quintile was 9.5 (8.3 to -), 5.4 (4.6-7.0), 3.8 (3.3-4.6), 3.2 (2.9-3.7) and 2.3 (2.1-2.6) years.

conclusionThe OTTA-SPOT (Ovarian Tumor Tissue Analysis consortium - Stratified Prognosis of Ovarian Tumours) gene expression signature may improve risk stratification in clinical trials by identifying patients who are least likely to achieve 5-year survival. The identified novel genes associated with the outcome may also yield opportunities for the development of targeted therapeutic approaches.

Indexed as

Cystadenocarcinoma, SerousOvarian NeoplasmsFemaleHumansPrognosisProportional Hazards ModelsSurvival AnalysisTranscriptomeformalin-fixed paraffin-embeddedgene expressionhigh-grade serous ovarian canceroverall survivalprognosis

Identifiers

PMID32473302
PMCPMC7484370

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.